Myelin oligodendrocyte glycoprotein antibody-associated disease: an immunopathological study.


Journal

Brain : a journal of neurology
ISSN: 1460-2156
Titre abrégé: Brain
Pays: England
ID NLM: 0372537

Informations de publication

Date de publication:
01 05 2020
Historique:
received: 22 02 2019
revised: 31 07 2019
accepted: 17 02 2020
pubmed: 16 5 2020
medline: 15 12 2020
entrez: 16 5 2020
Statut: ppublish

Résumé

Conformation-sensitive antibodies against myelin oligodendrocyte glycoprotein (MOG) are detectable in patients with optic neuritis, myelitis, opticomyelitis, acute or multiphasic disseminated encephalomyelitis (ADEM/MDEM) and brainstem/cerebral cortical encephalitis, but are rarely detected in patients with prototypic multiple sclerosis. So far, there has been no systematic study on the pathological relationship between demyelinating lesions and cellular/humoral immunity in MOG antibody-associated disease. Furthermore, it is unclear whether the pathomechanisms of MOG antibody-mediated demyelination are similar to the demyelination patterns of multiple sclerosis, neuromyelitis optica spectrum disorders (NMOSD) with AQP4 antibody, or ADEM. In this study, we immunohistochemically analysed biopsied brain tissues from 11 patients with MOG antibody-associated disease and other inflammatory demyelinating diseases. Patient median onset age was 29 years (range 9-64), and the median interval from attack to biopsy was 1 month (range 0.5-96). The clinical diagnoses were ADEM (n = 2), MDEM (n = 1), multiple brain lesions without encephalopathy (n = 3), leukoencephalopathy (n = 3) and cortical encephalitis (n = 2). All these cases had multiple/extensive lesions on MRI and were oligoclonal IgG band-negative. Most demyelinating lesions in 10 of 11 cases showed a perivenous demyelinating pattern previously reported in ADEM (153/167 lesions) and a fusion pattern (11/167 lesions) mainly in the cortico-medullary junctions and white matter, and only three lesions in two cases showed confluent demyelinated plaques. In addition, 60 of 167 demyelinating lesions (mainly in the early phase) showed MOG-dominant myelin loss, but relatively preserved oligodendrocytes, which were distinct from those of AQP4 antibody-positive NMOSD exhibiting myelin-associated glycoprotein-dominant oligodendrogliopathy. In MOG antibody-associated diseases, MOG-laden macrophages were found in the perivascular spaces and demyelinating lesions, and infiltrated cells were abundant surrounding multiple blood vessels in and around the demyelinating lesions, mainly consisting of macrophages (CD68; 1814 ± 1188 cells/mm2), B cells (CD20; 468 ± 817 cells/mm2), and T cells (CD3; 2286 ± 1951 cells/mm2), with CD4-dominance (CD4+ versus CD8+; 1281 ± 1196 cells/mm2 versus 851 ± 762 cells/mm2, P < 0.01). Humoral immunity, evidenced by perivascular deposits of activated complements and immunoglobulins, was occasionally observed in some MOG antibody-associated demyelinating lesions, and the frequency was much lower than that in AQP4 antibody-positive NMOSD. Subpial lesions with perivenous demyelination were observed in both ADEM and cortical encephalitis. Our study suggests that ADEM-like perivenous inflammatory demyelination with MOG-dominant myelin loss is a characteristic finding of MOG antibody-associated disease regardless of whether the diagnostic criteria of ADEM are met. These pathological features are clearly different from those of multiple sclerosis and AQP4 antibody-positive NMOSD, suggesting an independent autoimmune demyelinating disease entity.

Identifiants

pubmed: 32412053
pii: 5837518
doi: 10.1093/brain/awaa102
doi:

Substances chimiques

Autoantibodies 0
Autoantigens 0
MOG protein, human 0
Myelin-Oligodendrocyte Glycoprotein 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1431-1446

Investigateurs

Yoshihisa Otsuka (Y)
Keiichi Nishimaki (K)
Sho Ishigaki (S)
Kazunari Yoshida (K)
Yasuyuki Iguchi (Y)
Takahiro Fukuda (T)
Seitaro Nohara (S)
Akira Tamaoka (A)
Juichi Fujimori (J)

Informations de copyright

© The Author(s) (2020). Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Auteurs

Yoshiki Takai (Y)

Department of Neurology, Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan.

Tatsuro Misu (T)

Department of Neurology, Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan.
Department of Multiple Sclerosis Therapeutics, Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan.

Kimihiko Kaneko (K)

Department of Neurology, Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan.
Department of Neurology, National Hospital Organization Miyagi National Hospital, Watari, Miyagi, Japan.

Norio Chihara (N)

Division of Neurology, Kobe University Graduate School of Medicine, Kobe, Hyogo, Japan.

Koichi Narikawa (K)

Department of Neurology, Japanese Red Cross Ishinomaki Hospital, Ishinomaki, Miyagi, Japan.

Satoko Tsuchida (S)

Department of Pediatrics, Japanese Red Cross Akita Hospital, Akita, Akita, Japan.

Hiroya Nishida (H)

Department of Neuropediatrics, Tokyo Metropolitan Neurological Hospital, Fuchu, Tokyo, Japan.

Takashi Komori (T)

Department of Laboratory Medicine and Pathology, Tokyo Metropolitan Neurological Hospital, Fuchu, Tokyo, Japan.

Morinobu Seki (M)

Department of Neurology, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan.

Teppei Komatsu (T)

Department of Neurology, the Jikei University School of Medicine, Minato-ku, Tokyo, Japan.

Kiyotaka Nakamagoe (K)

Department of Neurology, Division of Clinical Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan.

Toshimasa Ikeda (T)

Department of Neuropathology, Institute for Medical Science of Aging, Aichi Medical University, Nagakute, Aichi, Japan.

Mari Yoshida (M)

Department of Neuropathology, Institute for Medical Science of Aging, Aichi Medical University, Nagakute, Aichi, Japan.

Toshiyuki Takahashi (T)

Department of Neurology, National Hospital Organization Yonezawa National Hospital, Yonezawa, Yamagata, Japan.

Hirohiko Ono (H)

Department of Neurology, Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan.

Shuhei Nishiyama (S)

Department of Neurology, Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan.

Hiroshi Kuroda (H)

Department of Neurology, Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan.

Ichiro Nakashima (I)

Department of Neurology, Tohoku Medical and Pharmaceutical University, Sendai, Miyagi, Japan.

Hiroyoshi Suzuki (H)

Department of Pathology, National Hospital Organization Sendai Medical Center, Sendai, Miyagi, Japan.

Monika Bradl (M)

Department of Neuroimmunology, Center for Brain Research, Medical University of Vienna, Vienna, Austria.

Hans Lassmann (H)

Department of Neuroimmunology, Center for Brain Research, Medical University of Vienna, Vienna, Austria.

Kazuo Fujihara (K)

Department of Neurology, Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan.
Department of Multiple Sclerosis Therapeutics, Fukushima Medical University, Fukushima, Fukushima, Japan.

Masashi Aoki (M)

Department of Neurology, Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH